AffaMed Therapeutics Announces First Patient Dosed in the US Phase I Clinical Trial of AM712 in Retinal Disease

AffaMed Therapeutics announced that the first patient has been dosed in its US Phase I study of AM712 (ASKG712), a novel proprietary bispecific biologic molecule blocking both VEGF and angiopoietin-2 for the treatment of retinal diseases.